Evidence supporting the use of: Anti-aromatase
For the health condition: Endometriosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Anti-aromatase agents are used in the management of endometriosis based on their mechanism of action and emerging clinical evidence. Endometriosis is an estrogen-dependent condition, and the aromatase enzyme is responsible for the conversion of androgens to estrogens. Research has shown that endometriotic tissue expresses aromatase, leading to local estrogen production that fuels lesion growth and inflammation. By inhibiting aromatase, agents such as letrozole and anastrozole reduce estrogen synthesis both systemically and locally within endometriotic lesions.

Clinical studies, though limited in size and number, have demonstrated that aromatase inhibitors can reduce endometriosis-related pain and lesion size, especially in women who do not respond to first-line hormonal therapies. Most studies combine aromatase inhibitors with other agents (like progestins or GnRH analogues) to prevent ovarian stimulation and cyst development, as aromatase inhibitors alone may increase gonadotropin levels. Side effects and potential bone loss limit long-term use, so these drugs are typically reserved for refractory cases. Overall, while not a first-line therapy, there is moderate scientific evidence supporting anti-aromatase agents for specific endometriosis cases, and their use is included in some clinical guidelines for difficult-to-treat patients.

More about anti-aromatase
More about Endometriosis

Products containing anti-aromatase

We currently have no products on Vitabase that contain this ingredient.